Short Interest in iRadimed Corporation (NASDAQ:IRMD) Expands By 25.1%

iRadimed Corporation (NASDAQ:IRMD) was the target of a large growth in short interest during the month of December. As of December 31st, there was short interest totaling 388,071 shares, a growth of 25.1% from the December 15th total of 310,250 shares. Based on an average trading volume of 79,534 shares, the days-to-cover ratio is currently 4.9 days. Currently, 4.8% of the shares of the company are sold short. Currently, 4.8% of the shares of the company are sold short. Based on an average trading volume of 79,534 shares, the days-to-cover ratio is currently 4.9 days.

iRadimed Stock Down 0.6%

iRadimed stock traded down $0.57 during mid-day trading on Monday, hitting $102.00. 67,470 shares of the company’s stock traded hands, compared to its average volume of 68,618. iRadimed has a one year low of $47.48 and a one year high of $103.06. The firm has a 50 day moving average price of $94.73 and a 200 day moving average price of $78.78. The company has a market cap of $1.30 billion, a PE ratio of 61.82 and a beta of 1.09.

iRadimed (NASDAQ:IRMD) last released its quarterly earnings results on Monday, November 3rd. The medical equipment provider reported $0.47 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.43 by $0.04. iRadimed had a return on equity of 22.93% and a net margin of 26.31%.The company had revenue of $21.20 million during the quarter, compared to analysts’ expectations of $20.50 million. iRadimed has set its Q4 2025 guidance at 0.470-0.510 EPS and its FY 2025 guidance at 1.840-1.880 EPS. On average, analysts expect that iRadimed will post 1.66 earnings per share for the current fiscal year.

iRadimed Dividend Announcement

The business also recently declared a special dividend, which was paid on Tuesday, December 30th. Shareholders of record on Wednesday, December 17th were given a dividend of $0.50 per share. The ex-dividend date was Wednesday, December 17th. iRadimed’s payout ratio is 41.21%.

Analyst Upgrades and Downgrades

A number of equities research analysts recently weighed in on IRMD shares. Roth Capital set a $90.00 price objective on shares of iRadimed in a research report on Friday, October 31st. Lake Street Capital restated a “buy” rating and issued a $100.00 target price on shares of iRadimed in a research note on Monday, November 3rd. Zacks Research raised iRadimed to a “hold” rating in a report on Tuesday, November 4th. Weiss Ratings reissued a “buy (b-)” rating on shares of iRadimed in a report on Monday, December 29th. Finally, Wall Street Zen lowered iRadimed from a “strong-buy” rating to a “buy” rating in a research report on Sunday, October 26th. Four investment analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $87.33.

Insider Activity at iRadimed

In related news, CFO John Glenn sold 15,000 shares of the firm’s stock in a transaction on Thursday, December 11th. The stock was sold at an average price of $97.29, for a total transaction of $1,459,350.00. Following the transaction, the chief financial officer directly owned 7,362 shares in the company, valued at $716,248.98. This trade represents a 67.08% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CEO Roger E. Susi sold 5,000 shares of iRadimed stock in a transaction on Monday, January 12th. The stock was sold at an average price of $97.45, for a total transaction of $487,250.00. Following the completion of the transaction, the chief executive officer directly owned 2,272,500 shares of the company’s stock, valued at approximately $221,455,125. This represents a 0.22% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last three months, insiders have sold 60,000 shares of company stock worth $5,451,200. Corporate insiders own 36.80% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the stock. USA Financial Formulas acquired a new position in iRadimed during the fourth quarter worth about $82,000. DAVENPORT & Co LLC bought a new position in shares of iRadimed during the 4th quarter valued at about $233,000. SG Americas Securities LLC boosted its position in shares of iRadimed by 88.6% during the 4th quarter. SG Americas Securities LLC now owns 70,391 shares of the medical equipment provider’s stock valued at $6,848,000 after purchasing an additional 33,072 shares in the last quarter. Tudor Investment Corp ET AL acquired a new position in shares of iRadimed in the 3rd quarter worth approximately $666,000. Finally, PharVision Advisers LLC bought a new stake in shares of iRadimed in the 3rd quarter worth approximately $257,000. 92.34% of the stock is currently owned by institutional investors.

iRadimed Company Profile

iRadimed Corporation designs, develops and manufactures medical device solutions for MRI environments. The company’s core product line consists of MRI-compatible infusion systems engineered to deliver precise fluid management during magnetic resonance imaging procedures. These devices are crafted to minimize electrical noise and interference, ensuring both patient safety and image clarity in diagnostic and interventional settings.

In addition to infusion pumps, iRadimed offers a range of complementary accessories and monitoring solutions tailored to MRI suites.